Find, compare & contact
Copper oxodotreotide Cu-64
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Copper oxodotreotide Cu-64 API 1426155-87-4?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Copper oxodotreotide Cu-64. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Copper oxodotreotide Cu-64
- Synonyms:
- 64Cu-dotatate , Copper 64-DOTA-tate , Copper Cu-64 dotatate , Copper dotatate Cu-64 , Copper oxodotreotide Cu-64
- Cas Number:
- 1426155-87-4
- DrugBank number:
- DB15873
- Unique Ingredient Identifier:
- N3858377KC
General Description:
Copper oxodotreotide Cu-64, identified by CAS number 1426155-87-4, is a notable compound with significant therapeutic applications. Copper Cu 64 dotatate is a newly approved Cu labeled somatostatin analog and has several advantages over 68Ga-labeled somatostatin analogs for positron emission tomography (PET). Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution. Further studies should be performed to compare the two tracers. Further, PET using Copper Cu 64 dotatate has been found to perform better than the current gold standard of single-photon emission computed tomography (SPECT) using 111In-DTPA-octreotide. In a head-to-head trial, the former tracer detected twice as many lesions as the latter.
Indications:
This drug is primarily indicated for: Copper Cu 64 Dotatate is a radiopharmaceutical used with positron emission tomography(PET) to locate somatostatin receptor-positive neuroendocrine tumors. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Absorption:
The absorption characteristics of Copper oxodotreotide Cu-64 are crucial for its therapeutic efficacy: Radioactivity can be identified in the kidney, liver, adrenal glands, spleen, and pituitary glands 1-3 hours after copper Cu 64 dotatate is administered. The drug's ability to rapidly penetrate into cells ensures quick onset of action.
Half-life:
The half-life of Copper oxodotreotide Cu-64 is an important consideration for its dosing schedule: The half-life of Copper Cu 64 is 12.7 hours. This determines the duration of action and helps in formulating effective dosing regimens.
Route of Elimination:
The elimination of Copper oxodotreotide Cu-64 from the body primarily occurs through: 16% - 40% of the original radioactivity was detected in urine 6 hours after the intravenous administration of a single dose. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.
Mechanism of Action:
Copper oxodotreotide Cu-64 functions by: The main target of the positron-emitting Copper Cu 64 dotatate is somatostatin receptor type 2 (SSTR2). SSTR2 is frequently overexpressed in malignant neuroendocrine cells; therefore, accumulation of the radionuclide at the site permits PET imaging to occur. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Toxicity:
Categories:
Copper oxodotreotide Cu-64 is categorized under the following therapeutic classes: Amino Acids, Peptides, and Proteins, Copper Radioisotopes, Peptides, Peptides, Cyclic, Positron Emitting Activity, Radioactive Diagnostic Agent, Radiopharmaceuticals. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Experimental Properties:
Further physical and chemical characteristics of Copper oxodotreotide Cu-64 include:
- Radioactivity: 1
Copper oxodotreotide Cu-64 is a type of Other substances
The pharmaceutical industry encompasses a diverse range of active pharmaceutical ingredients (APIs) that are used in the production of various medications. One category of APIs is known as other substances. This category includes substances that do not fall under the conventional classifications such as antibiotics, analgesics, or antihypertensives.
Other substances in pharmaceutical APIs consist of a broad array of chemical compounds with unique properties and applications. These substances play a crucial role in the formulation and development of specialized medications, catering to specific therapeutic needs. The category encompasses various substances like excipients, solvents, stabilizers, and pH adjusters.
Excipients are inert substances that aid in the manufacturing process and enhance the stability, bioavailability, and patient acceptability of pharmaceutical formulations. Solvents are used to dissolve other ingredients and facilitate their incorporation into the final product. Stabilizers ensure the integrity and shelf life of medications by preventing degradation or chemical changes. pH adjusters help maintain the desired pH level of a formulation, which can influence the drug's efficacy and stability.
Pharmaceutical manufacturers carefully select and incorporate specific other substances into their formulations, adhering to regulatory guidelines and quality standards. These substances undergo rigorous testing and evaluation to ensure their safety, efficacy, and compatibility with the desired pharmaceutical product. By employing other substances in API formulations, pharmaceutical companies can optimize drug delivery, improve patient compliance, and enhance therapeutic outcomes.
In summary, the other substances category of pharmaceutical APIs comprises a diverse range of chemicals, including excipients, solvents, stabilizers, and pH adjusters. These substances contribute to the formulation, stability, and performance of medications, enabling pharmaceutical manufacturers to develop specialized products that meet specific therapeutic requirements.
